Ovoca Bio plc Logo

Ovoca Bio plc

OVB.L

(1.0)
Stock Price

1,80 GBp

-34.21% ROA

-31.4% ROE

-0.84x PER

Market Cap.

997.666,85 GBp

0% DER

0% Yield

0% NPM

Ovoca Bio plc Stock Analysis

Ovoca Bio plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ovoca Bio plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.15x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

Negative ROE (-53.28%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-112.71%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Ovoca Bio plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ovoca Bio plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Ovoca Bio plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ovoca Bio plc Revenue
Year Revenue Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ovoca Bio plc Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 357.000 100%
2019 619.000 42.33%
2019 619.000 0%
2020 688.000 10.03%
2021 3.551.000 80.63%
2022 2.456.000 -44.58%
2023 4.000 -61300%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ovoca Bio plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 518.000 100%
2009 39.000 -1228.21%
2010 3.177.000 98.77%
2011 2.074.000 -53.18%
2012 2.487.000 16.61%
2013 1.838.000 -35.31%
2014 775.000 -137.16%
2015 547.000 -41.68%
2016 998.000 45.19%
2017 724.000 -37.85%
2018 589.000 -22.92%
2019 797.000 26.1%
2019 797.000 0%
2020 888.000 10.25%
2021 1.984.000 55.24%
2022 2.053.000 3.36%
2023 2.044.000 -0.44%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ovoca Bio plc EBITDA
Year EBITDA Growth
1988 -1.000
1989 -42.000 97.62%
1990 -333.000 87.39%
1991 -518.000 35.71%
1992 -6.000 -8533.33%
1993 -19.000 68.42%
1994 -69.000 72.46%
1996 755.000 109.14%
1997 -67.000 1226.87%
1998 -194.000 65.46%
1999 -189.000 -2.65%
2000 -198.000 4.55%
2001 -121.000 -63.64%
2002 -111.000 -9.01%
2003 -222.000 50%
2005 -902.000 75.39%
2006 4.047.000 122.29%
2007 -852.000 575%
2008 -810.000 -5.19%
2009 -517.000 -56.67%
2010 -4.164.000 87.58%
2011 -2.249.000 -85.15%
2012 -2.012.000 -11.78%
2013 -834.000 -141.25%
2014 -6.540.000 87.25%
2015 -1.360.000 -380.88%
2016 -1.133.000 -20.04%
2017 -482.000 -135.06%
2018 -1.472.000 67.26%
2019 -1.472.000 0%
2019 -1.807.000 18.54%
2020 -2.235.000 19.15%
2021 -5.142.000 56.53%
2022 -4.710.000 -9.17%
2023 -4.474.000 -5.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ovoca Bio plc Gross Profit
Year Gross Profit Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ovoca Bio plc Net Profit
Year Net Profit Growth
1988 -20.000
1989 -53.000 62.26%
1990 -342.000 84.5%
1991 -519.000 34.1%
1992 -7.000 -7314.29%
1993 -20.000 65%
1994 -71.000 71.83%
1996 -446.000 84.08%
1997 -132.000 -237.88%
1998 -184.000 28.26%
1999 -175.000 -5.14%
2000 -172.000 -1.74%
2001 -146.000 -17.81%
2002 -230.000 36.52%
2003 -237.000 2.95%
2005 -804.000 70.52%
2006 -5.247.000 84.68%
2007 -855.000 -513.68%
2008 -8.609.000 90.07%
2009 2.042.000 521.6%
2010 -3.440.000 159.36%
2011 4.263.000 180.69%
2012 -2.231.000 291.08%
2013 -14.816.000 84.94%
2014 -6.645.000 -122.96%
2015 -2.222.000 -199.05%
2016 -959.000 -131.7%
2017 -381.000 -151.71%
2018 -2.356.000 83.83%
2019 -1.925.000 -22.39%
2019 -1.590.000 -21.07%
2020 -2.348.000 32.28%
2021 -5.496.000 57.28%
2022 -5.612.000 2.07%
2023 -4.746.000 -18.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ovoca Bio plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ovoca Bio plc Free Cashflow
Year Free Cashflow Growth
1991 -163.000
1992 -11.000 -1381.82%
1993 -149.000 92.62%
1994 -214.000 30.37%
1996 -223.000 4.04%
1997 -267.000 16.48%
1998 -498.000 46.39%
1999 -551.000 9.62%
2000 -451.000 -22.17%
2001 -364.000 -23.9%
2002 -8.000 -4450%
2003 -1.596.000 99.5%
2004 -520.000 -206.92%
2005 -4.149.000 87.47%
2006 -5.851.000 29.09%
2007 -8.107.000 27.83%
2008 -6.807.000 -19.1%
2009 3.127.000 317.68%
2010 -10.003.000 131.26%
2011 -1.351.000 -640.41%
2012 -3.958.000 65.87%
2013 -2.841.000 -39.32%
2014 -327.000 -768.81%
2015 924.000 135.39%
2016 -395.000 333.92%
2017 -1.232.000 67.94%
2018 -2.838.000 56.59%
2019 -700.000 -305.43%
2019 -2.800.000 75%
2020 -2.536.000 -10.41%
2021 -4.547.000 44.23%
2022 -5.206.000 12.66%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ovoca Bio plc Operating Cashflow
Year Operating Cashflow Growth
1991 -48.000
1992 11.000 536.36%
1993 -68.000 116.18%
1994 -2.000 -3300%
1996 -63.000 96.83%
1997 -55.000 -14.55%
1998 -353.000 84.42%
1999 -192.000 -83.85%
2000 -150.000 -28%
2001 -186.000 19.35%
2002 9.000 2166.67%
2003 -434.000 102.07%
2004 -370.000 -17.3%
2005 -463.000 20.09%
2006 -568.000 18.49%
2007 -1.540.000 63.12%
2008 222.000 793.69%
2009 3.409.000 93.49%
2010 2.449.000 -39.2%
2011 3.310.000 26.01%
2012 2.260.000 -46.46%
2013 -2.817.000 180.23%
2014 -327.000 -761.47%
2015 924.000 135.39%
2016 -394.000 334.52%
2017 -1.232.000 68.02%
2018 -2.838.000 56.59%
2019 -542.500 -423.13%
2019 -2.170.000 75%
2020 -2.111.000 -2.79%
2021 -4.376.000 51.76%
2022 -5.164.000 15.26%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ovoca Bio plc Capital Expenditure
Year Capital Expenditure Growth
1991 115.000
1992 22.000 -422.73%
1993 81.000 72.84%
1994 212.000 61.79%
1996 160.000 -32.5%
1997 212.000 24.53%
1998 145.000 -46.21%
1999 359.000 59.61%
2000 301.000 -19.27%
2001 178.000 -69.1%
2002 17.000 -947.06%
2003 1.162.000 98.54%
2004 150.000 -674.67%
2005 3.686.000 95.93%
2006 5.283.000 30.23%
2007 6.567.000 19.55%
2008 7.029.000 6.57%
2009 282.000 -2392.55%
2010 12.452.000 97.74%
2011 4.661.000 -167.15%
2012 6.218.000 25.04%
2013 24.000 -25808.33%
2014 0 0%
2015 0 0%
2016 1.000 100%
2017 0 0%
2018 0 0%
2019 157.500 100%
2019 630.000 75%
2020 425.000 -48.24%
2021 171.000 -148.54%
2022 42.000 -307.14%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ovoca Bio plc Equity
Year Equity Growth
1987 645.000
1988 1.023.000 36.95%
1989 1.687.000 39.36%
1990 1.639.000 -2.93%
1991 1.120.000 -46.34%
1992 1.122.000 0.18%
1993 1.867.000 39.9%
1994 1.795.000 -4.01%
1995 2.117.000 15.21%
1996 1.934.000 -9.46%
1997 2.180.000 11.28%
1998 3.289.000 33.72%
1999 3.286.000 -0.09%
2000 3.139.000 -4.68%
2001 3.388.000 7.35%
2002 3.159.000 -7.25%
2003 4.476.000 29.42%
2004 4.414.000 -1.4%
2005 10.597.000 58.35%
2006 30.828.000 65.63%
2007 46.055.000 33.06%
2008 38.201.000 -20.56%
2009 46.421.000 17.71%
2010 56.748.000 18.2%
2011 50.153.000 -13.15%
2012 48.625.000 -3.14%
2013 25.974.000 -87.21%
2014 22.459.000 -15.65%
2015 21.451.000 -4.7%
2016 23.471.000 8.61%
2017 22.403.000 -4.77%
2018 20.626.000 -8.62%
2019 23.836.000 13.47%
2020 18.552.000 -28.48%
2021 13.430.000 -38.14%
2022 7.635.000 -75.9%
2023 2.501.000 -205.28%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ovoca Bio plc Assets
Year Assets Growth
1987 658.000
1988 1.052.000 37.45%
1989 1.870.000 43.74%
1990 1.802.000 -3.77%
1991 1.238.000 -45.56%
1992 1.307.000 5.28%
1993 2.136.000 38.81%
1994 2.108.000 -1.33%
1995 2.404.000 12.31%
1996 2.112.000 -13.83%
1997 2.516.000 16.06%
1998 3.545.000 29.03%
1999 3.482.000 -1.81%
2000 3.346.000 -4.06%
2001 3.572.000 6.33%
2002 3.395.000 -5.21%
2003 4.644.000 26.89%
2004 4.628.000 -0.35%
2005 11.153.000 58.5%
2006 31.750.000 64.87%
2007 47.248.000 32.8%
2008 39.567.000 -19.41%
2009 48.260.000 18.01%
2010 69.983.000 31.04%
2011 63.282.000 -10.59%
2012 60.369.000 -4.83%
2013 28.431.000 -112.34%
2014 22.757.000 -24.93%
2015 21.720.000 -4.77%
2016 23.688.000 8.31%
2017 22.449.000 -5.52%
2018 21.801.000 -2.97%
2019 24.263.000 10.15%
2020 19.038.000 -27.45%
2021 14.771.000 -28.89%
2022 9.405.000 -57.05%
2023 3.468.000 -171.19%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ovoca Bio plc Liabilities
Year Liabilities Growth
1987 13.000
1988 29.000 55.17%
1989 183.000 84.15%
1990 163.000 -12.27%
1991 118.000 -38.14%
1992 185.000 36.22%
1993 269.000 31.23%
1994 313.000 14.06%
1995 287.000 -9.06%
1996 178.000 -61.24%
1997 336.000 47.02%
1998 256.000 -31.25%
1999 196.000 -30.61%
2000 207.000 5.31%
2001 184.000 -12.5%
2002 236.000 22.03%
2003 168.000 -40.48%
2004 214.000 21.5%
2005 556.000 61.51%
2006 922.000 39.7%
2007 1.193.000 22.72%
2008 1.366.000 12.66%
2009 1.839.000 25.72%
2010 13.235.000 86.11%
2011 13.129.000 -0.81%
2012 11.744.000 -11.79%
2013 2.457.000 -377.98%
2014 298.000 -724.5%
2015 269.000 -10.78%
2016 217.000 -23.96%
2017 46.000 -371.74%
2018 1.175.000 96.09%
2019 427.000 -175.18%
2020 486.000 12.14%
2021 1.341.000 63.76%
2022 1.770.000 24.24%
2023 967.000 -83.04%

Ovoca Bio plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-0.84x
Price To Sales Ratio
0x
POCF Ratio
-2.93
PFCF Ratio
-2.93
Price to Book Ratio
0.4
EV to Sales
0
EV Over EBITDA
2.09
EV to Operating CashFlow
6.88
EV to FreeCashFlow
6.88
Earnings Yield
-1.19
FreeCashFlow Yield
-0.34
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.1
Graham NetNet
0.03

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.29
ROE
-0.31
Return On Assets
-0.34
Return On Capital Employed
-0.47
Net Income per EBT
1
EBT Per Ebit
1.01
Ebit per Revenue
0
Effective Tax Rate
0.05

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.45
Return on Tangible Assets
-0.34
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,04
Book Value per Share
0,03
Tangible Book Value per Share
0.03
Shareholders Equity per Share
0.03
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
2.98
Current Ratio
3.59
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
2501000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
13000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ovoca Bio plc Dividends
Year Dividends Growth

Ovoca Bio plc Profile

About Ovoca Bio plc

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

CEO
Mr. Timothy Rand McCutcheon
Employee
5
Address
17 Pembroke Street Upper
Dublin, 2

Ovoca Bio plc Executives & BODs

Ovoca Bio plc Executives & BODs
# Name Age
1 Mr. Timothy Rand McCutcheon
Chief Executive Officer & Director
70
2 Mr. Dmitriy Nikitashenko
Vice President of Finance
70
3 Reneta Nikolova
Corporate Secretary
70

Ovoca Bio plc Competitors

Nuformix plc Logo
Nuformix plc

NFX.L

(1.5)
N4 Pharma Plc Logo
N4 Pharma Plc

N4P.L

(1.0)
ImmuPharma plc Logo
ImmuPharma plc

IMM.L

(0.8)